Payment overview · 2025
General Payments
$2,086.59
81 reported records · 20 companies
Healthcare provider profile · identity verified
Paul Jay Katz, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MEMPHIS, TN · NPI 1497753131
Verified facts
What the public records show
CMS Open Payments records show Paul Jay Katz, MD received $2,086.59 in general payments during 2025 across 81 reported records.
Novo Nordisk Inc accounted for 22.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Linzess, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 215 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $477.97 | 22.9% | 12 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $394.79 | 18.9% | 14 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $249.89 | 12.0% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $159.28 | 7.6% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $156.16 | 7.5% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $141.23 | 6.8% | 2 | 2025 |
| C2N Diagnostics, LLC | Unresolved — no canonical attribution shown | $100.92 | 4.8% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $85.24 | 4.1% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $53.27 | 2.5% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $43.58 | 2.1% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.18 | 1.6% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $31.87 | 1.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.00 | 1.4% | 2 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $26.21 | 1.3% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $21.58 | 1.0% | 1 | 2025 |
| Ascensia Diabetes Care Us Inc. | Unresolved — no canonical attribution shown | $17.45 | 0.8% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.46 | 0.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.22 | 0.8% | 1 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $16.07 | 0.8% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.22 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,086.59 | 81 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $324.78 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $213.77 | 6 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $170.66 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $153.19 | 6 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $133.99 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $119.52 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $115.90 | 3 | 2025 |
Source payment records
|
|||||
| PRECIVITYAD2 Normalized: precivityad2 |
Device | C2N Diagnostics, LLC | $100.92 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $92.46 | 5 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $92.46 | 5 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $92.46 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $88.91 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $85.24 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $69.91 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $65.47 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $64.22 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $63.70 | 7 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $63.70 | 7 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $61.85 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $53.27 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $47.25 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $43.58 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $34.18 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $33.64 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $31.87 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $29.00 | 2 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $26.21 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $26.21 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $21.71 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $21.58 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.46 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $15.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 69 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 157 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 72 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 169 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 56 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
72 | 26 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
122 | 38 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
69 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
157 | 38 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
61 | 51 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
56 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
157 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
133 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
77 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
169 | 33 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
215 | 48 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
52 | 50 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1222 | 369 |
| Amlodipine Besylate | Amlodipine Besylate | 970 | 307 |
| Levothyroxine Sodium | Levothyroxine Sodium | 541 | 143 |
| Metformin Hcl | Metformin Hcl | 482 | 142 |
| Pantoprazole Sodium | Pantoprazole Sodium | 455 | 156 |
| Gabapentin | Gabapentin | 450 | 133 |
| Omeprazole | Omeprazole | 437 | 122 |
| Meloxicam | Meloxicam | 406 | 134 |
| Alprazolam | Alprazolam | 374 | 61 |
| Montelukast Sodium | Montelukast Sodium | 360 | 124 |
| Simvastatin | Simvastatin | 317 | 86 |
| Lisinopril | Lisinopril | 307 | 96 |
| Zolpidem Tartrate | Zolpidem Tartrate | 303 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 299 | 88 |
| Pravastatin Sodium | Pravastatin Sodium | 294 | 93 |
| Fluticasone Propionate | Fluticasone Propionate | 285 | 130 |
| Losartan Potassium | Losartan Potassium | 280 | 93 |
| Metoprolol Succinate | Metoprolol Succinate | 276 | 86 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 258 | 81 |
| Furosemide | Furosemide | 255 | 83 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 237 | 65 |
| Eliquis | Apixaban | 215 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 213 | 56 |
| Escitalopram Oxalate | Escitalopram Oxalate | 212 | 61 |
| Lorazepam | Lorazepam | 206 | 33 |
| Carvedilol | Carvedilol | 205 | 75 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 203 | 58 |
| Allopurinol | Allopurinol | 199 | 60 |
| Hydrochlorothiazide | Hydrochlorothiazide | 188 | 66 |
| Azithromycin | Azithromycin | 185 | 150 |
| Duloxetine Hcl | Duloxetine Hcl | 183 | 53 |
| Potassium Chloride | Potassium Chloride | 180 | 62 |
| Ezetimibe | Ezetimibe | 176 | 50 |
| Clonazepam | Clonazepam | 174 | 36 |
| Ozempic | Semaglutide | 169 | 33 |
| Valsartan | Valsartan | 163 | 50 |
| Glimepiride | Glimepiride | 158 | 50 |
| Jardiance | Empagliflozin | 157 | 38 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 157 | 45 |
| Sertraline Hcl | Sertraline Hcl | 152 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 149 | 50 |
| Methylprednisolone | Methylprednisolone | 148 | 117 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 145 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 142 | 54 |
| Trazodone Hcl | Trazodone Hcl | 139 | 35 |
| Spironolactone | Spironolactone | 136 | 43 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 135 | 44 |
| Mounjaro | Tirzepatide | 133 | 23 |
| Diazepam | Diazepam | 129 | 24 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 126 | 37 |
| Celecoxib | Celecoxib | 125 | 37 |
| Atenolol | Atenolol | 124 | 29 |
| Synthroid | Levothyroxine Sodium | 122 | 38 |
| Tramadol Hcl | Tramadol Hcl | 122 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 119 | 33 |
| Pioglitazone Hcl | Pioglitazone Hcl | 110 | 37 |
| Hydralazine Hcl | Hydralazine Hcl | 108 | 41 |
| Chlorthalidone | Chlorthalidone | 105 | 35 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 105 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 105 | 50 |
| Clonidine Hcl | Clonidine Hcl | 104 | 31 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 100 | 23 |
| Buspirone Hcl | Buspirone Hcl | 99 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 97 | 31 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 96 | 67 |
| Metformin Hcl Er | Metformin Hcl | 90 | 25 |
| Januvia | Sitagliptin Phosphate | 86 | 22 |
| Benazepril Hcl | Benazepril Hcl | 85 | 27 |
| Pregabalin | Pregabalin | 84 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 81 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 79 | 21 |
| Bupropion Xl | Bupropion Hcl | 78 | 23 |
| Trulicity | Dulaglutide | 77 | 12 |
| Cefuroxime | Cefuroxime Axetil | 76 | 71 |
| Meclizine Hcl | Meclizine Hcl | 76 | 39 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 75 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 75 | 27 |
| Linzess | Linaclotide | 72 | 26 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 71 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 70 | 18 |
| Farxiga | Dapagliflozin Propanediol | 69 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 66 | 55 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 63 | 14 |
| Famotidine | Famotidine | 62 | 18 |
| Donepezil Hcl | Donepezil Hcl | 61 | 20 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 61 | 51 |
| Xarelto | Rivaroxaban | 57 | 13 |
| Mirtazapine | Mirtazapine | 56 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 56 | 14 |
| Finasteride | Finasteride | 55 | 19 |
| Warfarin Sodium | Warfarin Sodium | 54 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 53 | 14 |
| Fenofibrate | Fenofibrate | 53 | 14 |
| Fluconazole | Fluconazole | 53 | 26 |
| Memantine Hcl | Memantine Hcl | 53 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 52 | 50 |
| Valacyclovir | Valacyclovir Hcl | 52 | 30 |
| Lansoprazole | Lansoprazole | 50 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 50 | 19 |
| Nifedipine Er | Nifedipine | 48 | 11 |
| Estradiol | Estradiol | 47 | 17 |
| Terazosin Hcl | Terazosin Hcl | 47 | 12 |
| Telmisartan | Telmisartan | 46 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 45 | 13 |
| Doxepin Hcl | Doxepin Hcl | 45 | 16 |
| Colchicine | Colchicine | 44 | 19 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 43 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 43 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 42 | 18 |
| Ramipril | Ramipril | 42 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 42 | 11 |
| Sucralfate | Sucralfate | 42 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 28 |
| Baclofen | Baclofen | 41 | suppressed |
| Nabumetone | Nabumetone | 40 | 14 |
| Nortriptyline Hcl | Nortriptyline Hcl | 39 | suppressed |
| Tradjenta | Linagliptin | 39 | suppressed |
| Acyclovir | Acyclovir | 38 | suppressed |
| Eszopiclone | Eszopiclone | 38 | suppressed |
| Irbesartan | Irbesartan | 38 | 12 |
| Alendronate Sodium | Alendronate Sodium | 37 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 37 | suppressed |
| Lovastatin | Lovastatin | 37 | suppressed |
| Prednisone | Prednisone | 37 | 21 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 36 | 31 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 35 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 34 | suppressed |
| Dutasteride | Dutasteride | 34 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 34 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | suppressed |
| Indapamide | Indapamide | 32 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | suppressed |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 31 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 30 | suppressed |
| Torsemide | Torsemide | 30 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 29 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 29 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 29 | suppressed |
| Livalo | Pitavastatin Calcium | 29 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 28 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 27 | suppressed |
| Cephalexin | Cephalexin | 27 | 20 |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 27 | 11 |
| Hydrocortisone | Hydrocortisone | 27 | 16 |
| Ibuprofen | Ibuprofen | 27 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | suppressed |
| Levofloxacin | Levofloxacin | 27 | 23 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 27 | 11 |
| Topiramate | Topiramate | 27 | suppressed |
| Glipizide | Glipizide | 26 | 12 |
| Glipizide Er | Glipizide | 26 | suppressed |
| Rybelsus | Semaglutide | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 23 |
| Risperidone | Risperidone | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Repatha Sureclick | Evolocumab | 24 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 23 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 18 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Kerendia | Finerenone | 21 | suppressed |
| Methimazole | Methimazole | 21 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Verapamil Er | Verapamil Hcl | 21 | suppressed |
| Invokana | Canagliflozin | 20 | suppressed |
| Loperamide | Loperamide Hcl | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Premarin | Estrogens, Conjugated | 20 | suppressed |
| Testosterone | Testosterone | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 17 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 18 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 18 | suppressed |
| Clotrimazole | Clotrimazole | 18 | 15 |
| Fentanyl | Fentanyl | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 16 | 16 |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Cartia Xt | Diltiazem Hcl | 16 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Nystatin | Nystatin | 16 | 14 |
| Phenobarbital | Phenobarbital | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 15 | suppressed |
| Prolia | Denosumab | 15 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 14 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 14 | suppressed |
| Methscopolamine Bromide | Methscopolamine Bromide | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | 12 |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Amlodipine-Valsartan-Hctz | Amlodipine/Valsartan/Hcthiazid | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | 11 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,086.59 · 81 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, BREZTRI, CAPLYTA, COMIRNATY, CREON, EVENITY, FARXIGA, FREESTYLE LIBRE, Fluad, Flucelvax, IBSRELA, JARDIANCE, KISUNLA, Kerendia, Korlym, LINZESS, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PRECIVITYAD2, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, WATCHMAN FLX, Wegovy, ZAVZPRET, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error